Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab plus XELOX or FOLFOX-4 vs FOLFOX-4 alone as adjuvant chemotherapy in colon carcinoma
2004-000715-26Phase 3Completed
- Sponsor
- Roche
- Start
- Nov 2004
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of bevacizumab in colon cancer (3 arms), sponsored by Roche. Primary endpoint: Disease-free survival. Started Nov 2004; status: completed.
02
Drugs
bevacizumab
03
Conditions
colon cancer
Beyond the preview
Go deeper on 2004-000715-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000715-26.